These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 19860198)
1. [Treatment of myeloproliferative neoplasms other than chronic leukemia]. Ohyashiki JH Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198 [TBL] [Abstract][Full Text] [Related]
2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [TBL] [Abstract][Full Text] [Related]
4. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
5. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Tefferi A Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582 [TBL] [Abstract][Full Text] [Related]
7. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Poodt J; Fijnheer R; Walsh IB; Hermans MH Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961 [TBL] [Abstract][Full Text] [Related]
8. [JAK2 mutation and thrombosis - recommendations for screening]. Linnemann B; Lindhoff-Last E Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574 [No Abstract] [Full Text] [Related]
9. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Finazzi G; Barbui T Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737 [TBL] [Abstract][Full Text] [Related]
10. Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders. Hsu HC J Chin Med Assoc; 2007 Mar; 70(3):89-93. PubMed ID: 17389152 [TBL] [Abstract][Full Text] [Related]
11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Zhan H; Spivak JL Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323 [TBL] [Abstract][Full Text] [Related]
12. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Tefferi A Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051 [TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Oh ST; Gotlib J Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983 [TBL] [Abstract][Full Text] [Related]
15. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A; Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858 [TBL] [Abstract][Full Text] [Related]
16. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms]. Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698 [TBL] [Abstract][Full Text] [Related]
17. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Plo I; Vainchenker W Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861 [TBL] [Abstract][Full Text] [Related]
18. Management of polycythemia vera and essential thrombocythemia. Campbell PJ; Green AR Hematology Am Soc Hematol Educ Program; 2005; ():201-8. PubMed ID: 16304381 [TBL] [Abstract][Full Text] [Related]